News

 

 

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients

AB-SA01 meets primary endpoints of safety and tolerability and reduces S. aureus bacterial load in all patients

Read more about AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01

Business update call scheduled for January 4, 2017 at 4:30 p.m. Eastern

Read more about AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01

AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public offering of...

Read more about AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

Adherium's Smartinhaler selected for multisite study in EU

Melbourne, Australia-based smart inhaler company Adherium has been selected to supply the technology for a multi-country research program in Europe that will seek to establish whether home monitoring and mobile...

Read more about Adherium's Smartinhaler selected for multisite study in EU

AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced financial results for the third quarter ended...

Read more about AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Quarterly Report and Update from CEO

CEO Shareholder Letter and Quarterly Report Dear Shareholder, link here

Read more about Quarterly Report and Update from CEO

U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries

U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries • Up to 48 patients can now be treated at 15 US burnscenters • Increased...

Read more about U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries

Avita Medical to Participate in the 3rd annual Biotech and Money / Medtech and Money London 2017 Conference

Northridge, CA, Perth, Australia and London, United Kingdom – 25 January 2017 – link here.

Read more about Avita Medical to Participate in the 3rd annual Biotech and Money / Medtech and Money London 2017 Conference

BioScience Managers partners with large UK Venture Capital Trust Fund

Monsoon Communications 13 December 2016

Leading life sciences investment group BioScience Managers has partnered with London based investment firm Downing LLP to offer a new Healthcare Share Class to VCT investors.

Read more about BioScience Managers partners with large UK Venture Capital Trust Fund

BioScience Managers Translation Fund to spur Australian jobs and innovation

Monsoon Communications 13 December 2016

BioScience Managers, one of Australia’s leading life sciences investment firms, has been awarded a $100 million investment licence for the Federal Government-backed Biomedical Translation Fund.

Read more about BioScience Managers Translation Fund to spur Australian jobs and innovation

1 2 3 4 5 6 ... 24